Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines-Reference-Cited by-同舟云学术

Omicron spike function and neutralizing activity elicited by a comprehensive panel of vaccines

Published:2022-08-19 Issue:6608 Volume:377 Page:890-894
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Bowen John E.¹^ORCID,Addetia Amin¹^ORCID,Dang Ha V.²^ORCID,Stewart Cameron¹^ORCID,Brown Jack T.¹^ORCID,Sharkey William K.¹,Sprouse Kaitlin R.¹^ORCID,Walls Alexandra C.¹³^ORCID,Mazzitelli Ignacio G.⁴^ORCID,Logue Jennifer K.⁵^ORCID,Franko Nicholas M.⁵^ORCID,Czudnochowski Nadine²^ORCID,Powell Abigail E.²^ORCID,Dellota Exequiel²,Ahmed Kumail⁶^ORCID,Ansari Asefa Shariq⁶^ORCID,Cameroni Elisabetta⁷^ORCID,Gori Andrea⁸⁹¹⁰^ORCID,Bandera Alessandra⁸⁹¹⁰^ORCID,Posavad Christine M.¹¹^ORCID,Dan Jennifer M.¹²¹³^ORCID,Zhang Zeli¹²,Weiskopf Daniela¹²^ORCID,Sette Alessandro¹²¹³^ORCID,Crotty Shane¹²¹³^ORCID,Iqbal Najeeha Talat⁶^ORCID,Corti Davide⁷^ORCID,Geffner Jorge⁴^ORCID,Snell Gyorgy²^ORCID,Grifantini Renata¹⁴^ORCID,Chu Helen Y.⁵^ORCID,Veesler David¹³^ORCID

Affiliation:

1. Department of Biochemistry, University of Washington, Seattle, WA 98195, USA.

2. Vir Biotechnology, San Francisco, CA 94158, USA.

3. Howard Hughes Medical Institute, University of Washington, Seattle, WA 98195, USA.

4. Instituto de Investigaciones Biomédicas en Retrovirus y SIDA (INBIRS), Facultad de Medicina, Buenos Aires C1121ABG, Argentina.

5. Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA 98195, USA.

6. Departments of Paediatrics and Child Health and Biological and Biomedical Sciences, Aga Khan University, Karachi 74800, Pakistan.

7. Humabs Biomed SA, a subsidiary of Vir Biotechnology, 6500 Bellinzona, Switzerland.

8. Infectious Diseases Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy.

9. Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy.

10. Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy.

11. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.

12. Center for Infectious Disease and Vaccine Research, La Jolla Institute for Immunology, La Jolla, CA 92037, USA.

13. Department of Medicine, Division of Infectious Diseases and Global Public Health, University of California, San Diego, La Jolla, CA 92037, USA.

14. INGM, Istituto Nazionale Genetica Molecolare “Romeo ed Enrica Invernizzi,” Milan, Italy.

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern comprises several sublineages, with BA.2 and BA.2.12.1 having replaced the previously dominant BA.1 and with BA.4 and BA.5 increasing in prevalence worldwide. We show that the large number of Omicron sublineage spike mutations leads to enhanced angiotensin-converting enzyme 2 (ACE2) binding, reduced fusogenicity, and severe dampening of plasma neutralizing activity elicited by infection or seven clinical vaccines relative to the ancestral virus. Administration of a homologous or heterologous booster based on the Wuhan-Hu-1 spike sequence markedly increased neutralizing antibody titers and breadth against BA.1, BA.2, BA.2.12.1, BA.4, and BA.5 across all vaccines evaluated. Our data suggest that although Omicron sublineages evade polyclonal neutralizing antibody responses elicited by primary vaccine series, vaccine boosters may provide sufficient protection against Omicron-induced severe disease.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference83 articles.

1. SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern

2. Spread of a SARS-CoV-2 variant through Europe in the summer of 2020

3. Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants

4. Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement

5. SARS-CoV-2 breakthrough infections elicit potent, broad, and durable neutralizing antibody responses

Cited by 125 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deciphering the free energy landscapes of SARS-CoV-2 wild type and Omicron variant interacting with human ACE2;The Journal of Chemical Physics;2024-02-02

2. Microfluidic antibody profiling after repeated SARS-CoV-2 vaccination links antibody affinity and concentration to impaired immunity and variant escape in patients on anti-CD20 therapy;Frontiers in Immunology;2024-01-08

3. Innovation-driven trend shaping COVID-19 vaccine development in China;Frontiers of Medicine;2023-12-16

4. AlphaFold2-Enabled Atomistic Modeling of Epistatic Binding Mechanisms for the SARS-CoV-2 Spike Omicron XBB.1.5, EG.5 and FLip Variants: Convergent Evolution Hotspots Cooperate to Control Stability and Conformational Adaptability in Balancing ACE2 Binding and Antibody Resistance;2023-12-12

5. Humoral and cellular immunity against diverse SARS-CoV-2 variants;Journal of Genetics and Genomics;2023-12